论文部分内容阅读
１９８４年１月至１９９０年１月对７８例食管癌根治性放疗（Ｄ＿Ｔ６０～７０Ｇｙ／６～７周）后复发的患者，经前瞻性随机分组，分为手术切除组和再程放疗组进行对比治疗。手术切除组的切除率为８９．７％，术后并发症为２５．７％，手术死亡率达１１．４％。１、３、５年生存率分别为８２．８％、３４．５％和２７．６％；再程放疗组Ｄ＿Ｔ４０～６０Ｇｙ／４～６周，１、３、５年生存率分别为４０．５％、８．１％和２．７％。手术切除组的疗效明显好于再程放疗组（Ｐ＜０．０１），认为复发患者只要一般状况允许，无明显转移和无病变外侵累及气管膜部者，均应争取手术切除，尤以梗噎严重或较深溃疡者更应争取手术切除，以期得到更佳疗效。失去手术机会的患者，再程放疗仍为重要的治疗手段。
From January 1984 to January 1990, 78 patients with recurrent radiotherapy of esophageal cancer (D-T60-70 Gy/6 to 7 weeks) were randomized prospectively and divided into surgical resection group and reradiation group. treatment. The surgical resection rate was 89.7%, the postoperative complication was 25.7%, and the operative mortality rate was 11.4%. The 1-, 3-, and 5-year survival rates were 82.8%, 34.5%, and 27.6%, respectively; DRTs 40 to 60 Gy/4 to 6 weeks of reprogrammed radiotherapy group had 1-, 3-, and 5-year survival rates of 40. 5%, 8.1% and 2.7%. The curative effect of the surgical resection group was significantly better than that of the retransmission radiotherapy group (P<0.01). It was considered that the relapsed patients should strive for surgical resection as long as the general condition allows, no significant metastasis, and no external involvement of the lesions in the tracheal membrane. Those who have severe or deep-scald ulcers should strive for surgical resection in order to obtain better results. In patients who have lost surgery, reimaging radiotherapy remains an important treatment.